VANCOUVER, British Columbia, Sept. 17, 2019 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce that it has signed a first stage agreement in the form of a Letter of Intent (LOI) with Dubai based clinical research organization, Clinart, to

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Aug. 20, 2019 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to provide an update on the significant progress the company has made over the summer

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES  VANCOUVER, British Columbia, Aug. 13, 2019 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company“) announces that it has closed the first tranche of its previously announced non-brokered private placement by issuing

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES  VANCOUVER, British Columbia, Aug. 06, 2019 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) announces the appointment of Ms. Kiki Smith, CPA, CGA to the role of Chief Financial Officer, where

A correction from source is issued for the news release of even date. The news release has been corrected for the Warrant and Finder Warrant exercise prices. The corrected release follows:  NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES  VANCOUVER, British Columbia, July 11, 2019 (GLOBE

VANCOUVER, British Columbia, June 18, 2019 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) announces today additions and changes to its board and executive team as the Company continues to align itself for further growth in the year ahead. Sherif Guorgui is leaving the Board of

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce a non-brokered private placement of up to 21,428,571 units of the Company (the “Units”) at a price of $0.07 per Unit for aggregate gross proceeds of up to $1,500,000 (the “Private Placement”). Each Unit

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health”or the “Company”) reports that the Management Cease Trade Order granted by the British Columbia Security Commission on May 2, 2019 was lifted effective June 3, 2019 following the filing of the Company’s financial statements and accompanying management’s discussion and analysis for

Kevin Strong will serve as CFO and Deena Siblock takes on Corporate Secretary role, adding capacity and talent to the fast-growing healthcare technology leader, Avricore Health. Vancouver, May XX, 2019 – Avricore Health Inc. (TSXV: AVCR) (OTCBB: AVCR) (“Avricore Health”) is expanding its capacity to meet its objectives by adding

Avricore Health Inc. (TSXV:  AVCR) (“Avricore Health”) has signed a distribution agreement with Molecular You Corporation (“Molecular You”) to provide its newly developed genetic medication response test myCannabisPGxTM, which is designed to ensure safe and effective use of medical cannabis in a community pharmacy setting. During this launch phase, Avricore